title: Proton-pump inhibitor as palliative care for chemotherapy-induced gastroesophageal reflux disease in pancreatic cancer patients.
abstract: Relief of adverse events induced by chemotherapy is an important issue for patients, especially those with a poor prognosis, such as with pancreatic cancer. There are no reports of the relationship between gastroesophageal reflux disease (GERD) and chemotherapy, so we investigated the incidence of chemotherapy-induced GERD in patients undergoing treatment with gemcitabine or S-1 for pancreatic cancer and the effect of sodium rabeprazole (RPZ), a proton-pump inhibitor. GERD was diagnosed in 40% of the patients according to the Frequency Scale for Symptoms of GERD score, and RBZ therapy significantly improved their symptoms.
authors.affiliation: Department of Surgery, Jikei University School of Medicine, Tokyo, Japan. uwatadashi@msn.com
authors.forename: Tadashi
authors.initials: T
authors.lastname: Uwagawa
authors.forename: Takeyuki
authors.initials: T
authors.lastname: Misawa
authors.forename: Tomonori
authors.initials: T
authors.lastname: Iida
authors.forename: Taro
authors.initials: T
authors.lastname: Sakamoto
authors.forename: Takeshi
authors.initials: T
authors.lastname: Gocho
authors.forename: Shigeki
authors.initials: S
authors.lastname: Wakiyama
authors.forename: Shoichi
authors.initials: S
authors.lastname: Hirohara
authors.forename: Katsuhiko
authors.initials: K
authors.lastname: Yanaga
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use; D003841:Deoxycytidine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D004338:Drug Combinations; D005260:Female; D005764:Gastroesophageal Reflux / Q000139:chemically induced / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010094:Oxonic Acid / Q000008:administration & dosage / Q000627:therapeutic use; D010166:Palliative Care / Q000379:methods*; D010190:Pancreatic Neoplasms / Q000188:drug therapy*; D011446:Prospective Studies; D054328:Proton Pump Inhibitors / Q000627:therapeutic use*; D064750:Rabeprazole; D005641:Tegafur / Q000008:administration & dosage / Q000627:therapeutic use; D000093542:Gemcitabine
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D004338:Drug Combinations; D054328:Proton Pump Inhibitors; D003841:Deoxycytidine; C079198:S 1 (combination); D005641:Tegafur; D064750:Rabeprazole; D010094:Oxonic Acid; D000093542:Gemcitabine